Lumos Diagnostics, a rapid point-of-care diagnostics company spun out of Planet Innovation, has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.
Silicon Valley start-up Levitas Bio has launched the world’s first label-free cell separation platform, the LeviCell™.
Planet Innovation and Lumos Diagnostics have won two awards at the 2020 Good Design Awards, including a Good Design Award Gold accolade for Lumos’s Leelu Reader.
Atmo Biosciences has been awarded a $620,000 Australian Government grant through the BioMedTech Horizons (BMTH) program.
PI has partnered with Truvian, a healthcare company at the intersection of diagnostics and consumer technology, to develop a new point-of-care blood testing device to make routine health tests more convenient, affordable and actionable for consumers.
Atmo Biosciences, a digital health business that provides objective real-time insights into gut health and microbiome function, has raised a further A$2.5 million in an oversubscribed funding round, supplementing an initial seed raise in March 2019.
From start-ups to established companies, almost everyone in the life sciences and diagnostics industries is playing with digital health in one form or another. But how do you ensure this investment translates into commercial success for your company?
We are seeking GPs and other healthcare professionals in Victoria, Australia to pilot a new TGA-approved point-of-care test to help differentiate patients with viral from bacterial acute respiratory tract infections.
A roundup of the latest news and opinions from PI.
Planet Innovation has agreed to a $A20 million strategic investment in Lumos Diagnostics, a rapid point-of-care diagnostics company.
November 18-24 is World Antibiotic Awareness Week, so it’s a good time to draw attention to the global health challenge of antibiotic resistance, which Planet Innovation is combating through its business Lumos Diagnostics.
Lumos Diagnostics and RPS Diagnostics have merged to create a full-service point-of-care diagnostic development company and support the international commercialization of FebriDx.
Abbott Molecular’s VIP2000 was recognized for its innovative product design and engineering as a finalist at the prestigious Medical Design Excellence Awards (MDEAs) in New York.
PI has entered into an agreement with Imagion Biosystems, a company dedicated to improving healthcare through the earlier detection of cancer, to develop Imagion’s MagSense instrument technology.
This month’s Association for Molecular Pathology (AMP) 2018 Annual Meeting & Expo focused on the field of precision medicine. Experts from across the molecular diagnostic world gathered in San Antonio, Texas, to exchange knowledge and ideas, with the ultimate aim of creating better patient outcomes.
Atmo Biosciences, a Planet Innovation early stage venture, has signed a licensing deal with RMIT University to secure the exclusive worldwide rights to a ground-breaking ingestible gas-sensing capsule.
Lumos Diagnostics is expanding its global footprint after agreeing an ongoing manufacturing deal for a customized lateral flow reader with a California-based life sciences company.
An RMIT University researcher working with PI on technology that can test patients for bleeding or clotting disorders has been awarded more than $650,000 in NHMRC funding.
Clever Culture Systems has collected silver at the prestigious Medical Design Excellence Awards (MDEAs) for its innovative APAS Independence instrument, which Planet Innovation helped develop.
Planet Innovation today announced a partnership with Preora Healthcare Inc., pioneers in the detection of early-stage cancers, to bring to market a series of novel, low-cost, minimally invasive, highly accurate and easy-to-use cancer screening tests.
Lumos Diagnostics develops custom products for its partners using a unique combination of integrated assay and engineering capability paired with its proven reader optical technologies.
Planet Innovation’s PoC (Point-of-Care) diagnostic platform, Nplex, will benefit from further investment to develop a cloud-connected medical counter-measures device, for the rapid detection of infectious diseases.